Health Care

4326 posts
Sandoz logo

Avecho clocks $4.7M payment from pharma giant Sandoz for CBD capsule licence

Avecho (ASX:AVE) has received a US$3M (A$4.7M) payment from pharma heavyweight Sandoz in exchange for the…
Nerve cell concept

ReNerve jumps +45% as 13 patients report pain decrease follow nerve repair surgery

Renerve has popped nearly +50% after reporting 13 patients using ReNerve's 'Nerve Cuff' led to a…
FDA Approval

Artrya pops +11% on yet another FDA approval for an Aussie biotech

Artrya (ASX:AYA) is the latest Aussie biotech stock to see an FDA approval and consequent rewarding…
Molecules

Proteomics scores Aussie patent for oxidative stress blood test ‘attracting wide-range interest’

Proteomics International Laboratories Ltd has secured a patent in Australia for its OxiDx test to assess…
Mesoblast research conept

Mesoblast kicks off Ryoncil sales in US but shareholders eager for revenue

Mesoblast (ASX:MSB) has announced its product Ryoncil is officially available for sale in the US through…
Man uses spray

LTR Pharma dips -6% as US growth plans confuse with two identical products to be launched

LTR Pharma has revealed its latest plan to further expand into the U.S. – with a…
Clinuvel

Clinuvel stroke drug shows ‘positive’ results – but some adverse effects left unclear

Clinuvel shares jumped on Tuesday on higher volumes as the company reported a clinical trial win…
Lung cancer

Immutep notches upward on first lung cancer patient dosing

Immutep Ltd has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer…
Concerned shareholder

Opthea’s Phase 3 trial results fail to help patients, future of company at risk

It mightn't be too surprising that Opthea applied for a voluntary suspension last week ahead of…
Dices forming the acronym ALS

‘Maximising the potential’: Neurizon prepares for HEALEY study of ALS

Neurizon Therapeutics Ltd has provided an update to its preparations for the HEALEY Platform Trial to…